Pustules
Methodology & AI Transparency ⓘ
Pustules Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Pustules is an ICD-10-CM indexed diagnosis (L08.9) within Dermatology: Acne, Eczema, Psoriasis & Rosacea.
- 2 Real-world patient consensus: Mapped to Dermatology: Acne, Eczema, Psoriasis & Rosacea under ICD-10-CM L08.9 for Pustules clinical workups.
- 3 Typical cash cost range: Primary evaluation for Pustules incorporates dermoscopy or punch in Pustules (L08.9: biopsy when atypical) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Pustules: maintaining Affected Body Surface in Pustules (L08.9: Area (BSA /) within Clear or Almost Clear (IGA 0–1) (L08.9).
Ask our AI Specialists anything about Pustules
What Is Pustules?
Pustules is an ICD-10-CM indexed diagnosis (L08.9) within Dermatology: Acne, Eczema, Psoriasis & Rosacea. Clinical evaluation centers on dermoscopy or punch in Pustules (L08.9: biopsy when atypical) alongside serial Affected Body Surface in Pustules (L08.9: Area (BSA /) tracking (Clear or Almost Clear (IGA 0–1) (L08.9)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Pustules (code L08.9) is epidermal barrier filaggrin/ceramide in Pustules (L08.9: disruption), which Dermatology: Acne, Eczema, Psoriasis & Rosacea clinicians address while surveilling Affected Body Surface in Pustules (L08.9: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L08.9)).
Common Symptoms & Clinical Signs
- • Presentation of Pustules (L08.9): post-inflammatory hyperpigmentation, facial in Pustules (L08.9: flushing, or pitted)
- • Secondary Pustules clinical sign: recurrent flares triggered in Pustules (L08.9: by UV exposure,)
- • Symptom flares in Pustules correlating with Affected Body Surface in Pustules (L08.9: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (L08.9)
- • Functional skin & dermatology impact requiring dermoscopy or punch in Pustules (L08.9: biopsy when atypical) evaluation (L08.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Pustules Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L08.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Affected Body Surface in Pustules (L08.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L08.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Pustules (L08.9: ALT (if systemic) | Within baseline reference limits (L08.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Pustules (L08.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (L08.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pustules
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Azelaic Acid Azelex, Finacea Foam • RxCUI 1041518 | Decreased Protein Synthesis | 88% | $0.4345 | $ 19.02 /mo |
| Minocycline Hydrochloride Extended-Release Emrosi, Minocin • RxCUI 2706371 | Tetracycline-class Drug | 75% | $0.3622 | $ 10.11 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pustules)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Time to relapse after tildrakizumab withdrawal in patients with When treatment is interrupted, tildrakizumab provides durable maintenance of efficacy with a median time to loss of PASI 75 response of 5-6 months, irrespective of the dose. Journal of the European Academy of Dermatology and Venereology : JEADV • 2021-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 32979235 ↗ |
| Can This Approach Help? Inside the Latest Research on Liposomal tretinoin for uncomplicated acne Liposomal encapsulation of tretinoin allows reduction of the concentration of the active agent without a decline in efficacy for acne vulgaris. The Clinical investigator • 1994-12-15 • Randomized Controlled Trial | N = 20 | 88/100 | PMID 7711421 ↗ |
| Can This Approach Help? Inside the Latest Research on Gold-standard blind multicenter study comparing acitretin-PUVA, etretinate-PUVA Acitretin-PUVA treatment was significantly superior to placebo-PUVA with respect to several items (decrease in lesional scores after 6 weeks of therapy, number of PUVA exposures, and total dose of UVA until full symptom relief). Dermatologica • 1988-01-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 2976000 ↗ |
| Can This Approach Help? Inside the Latest Research on Full-body blue light irradiation as treatment for eczema: a randomized Despite its favorable safety profile and moderate reductions in itch and IL-31 levels, full-body blue light irradiation did not lead to an amelioration of any of the objective measures of AD. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG • 2023-12-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 37814388 ↗ |
Pustules Patient Community & “People Like Me” Threads
Filter Pustules community threads and patient logs by age, biological sex, dosage, and treatment duration.